Dudediligence.

NRx Pharmaceuticals, Inc

NRXPNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$0.00Sep ’24$0.00Dec ’24$0.00Mar ’25$242,000Sep ’25$983,000Dec ’25$1.1MMar ’26$1.1MJun ’26
Net income, by quarter
−$1.6MSep ’24−$9.1MDec ’24−$5.5MMar ’25−$17.6MJun ’25−$5.9MSep ’25$360,000Dec ’25−$1.4MMar ’26−$16.5MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenuenone on filenone on filenone on file$0.00$1.2M
Gross profitnone on filenone on filenone on file$0.00$720,000
Operating income−$115.8M−$44.3M−$27.8M−$18.5M−$16.2M
Net income−$93.1M−$39.8M−$30.1M−$25.1M−$28.6M
Operating cash flow−$37.7M−$39.8M−$21.7M−$10.6M−$14.1M
Free cash flow−$37.7M−$39.8M−$21.7M−$10.6Mnone on file
Cash$27.6M$20.1M$4.6M$1.4M$7.8M
Debtnone on file$10.5M$9.2Mnone on filenone on file
Shares outstanding58.8M66.4M8.4M14.6M31.7M